{"hq_id":"hq-c-org-000202","name":"Phencyclidine (PCP)","context":"human_adult","timestamp":"2026-10-27T20:51:13.325Z","derived_by":{"label":"ALETHEIA-derived","engine":{"commit":"a1c6e861599cc34c5db0318ea1a7ac13a327e074","commit_source":"vercel_env","tree_clean":null},"params":{"sha256":"88ae43137e58ed0cd65588409efefee0d90253da01ef4459bf9ee25f888ec9a0","files":["axes.json","context-specificity.json","regulatory-mappings.json","synthesis-params.json","thresholds.json"]},"clock":{"year":2026},"inputs":[{"id":"hq-c-org-000202","sha256":"6b40e9e2743ff588a37a03d3925dace3eae5f0c7d8773eeb486eb3942ffc7c8b"}]},"risk_level":"high","risk_profile":{"magnitude":{"mean":0.625,"weightedMean":0.625,"std_dev":0,"confidence_interval_95":[0.625,0.625],"source_positions":[{"source":"HQ_DIRECT","year":2026,"value":0.625,"weight":0.35}]},"confidence":{"mean":0.5,"weightedMean":0.5,"std_dev":0,"confidence_interval_95":[0.5,0.5],"source_positions":[{"source":"HQ_DIRECT","year":2026,"value":0.5,"weight":0.35}]},"recency":{"mean":1,"weightedMean":1,"std_dev":0,"confidence_interval_95":[1,1],"source_positions":[{"source":"HQ_DIRECT","year":2026,"value":1,"weight":0.35}]},"methodology":{"mean":0.7,"weightedMean":0.7,"std_dev":0,"confidence_interval_95":[0.7,0.7],"source_positions":[{"source":"HQ_DIRECT","year":2026,"value":0.7,"weight":0.35}]},"specificity":{"mean":0.92,"weightedMean":0.92,"std_dev":0,"confidence_interval_95":[0.92,0.92],"source_positions":[{"source":"HQ_DIRECT","year":2026,"value":0.92,"weight":0.35}]},"consensus":{"exists":false,"strength":0,"disagreement_magnitude":0,"warning":"single_source_warning"}},"interpretation":{"summary":"Single source (HQ_DIRECT, 2026) indicates high risk.","confidence_note":"Evidence quality varies; interpretation requires caution.","context_note":null,"warning":"single_source_warning"},"sources":[{"id":"dea_pcp_schedule_ii","type":"regulatory","title":"US DEA: Phencyclidine (PCP) — Schedule II Classification, NMDA Receptor Antagonism, Schizophrenia Model Drug, Clinical Toxidrome (Nystagmus, Dissociation, Analgesia, Agitation), and Veterinary Sernylan History (2022)","year":2022},{"id":"goldfrank_pcp_toxicology","type":"academic","title":"Goldfrank's Toxicologic Emergencies: Phencyclidine and Ketamine — NMDA Antagonist Toxidrome, Nystagmus Triad, Hyperthermia Risk with Physical Restraint, Benzodiazepine Management, and Differential Diagnosis from Excited Delirium (11th Ed., 2019)","year":2019},{"id":"r60-2026-09-30-d918-oehha-prop65-list-csv-own-url","type":"regulatory","title":"OEHHA Proposition 65 List of Carcinogens or Reproductive Toxicants (CSV, list date 31-Jul-26)","url":"https://oehha.ca.gov/sites/default/files/media/2025-01/p65chemicalslist.csv"},{"id":"pubchem-exp-drugbank-cid-6468","type":"database","title":"DrugBank, as recorded by PubChem (Experimental Properties, CID 6468; where-to-look, not a source of this value)","year":2026,"url":"https://pubchem.ncbi.nlm.nih.gov/rest/pug_view/data/compound/6468/JSON?heading=Experimental+Properties"},{"id":"ctx_pred_dtxsid6023446","type":"reference","title":"EPA CompTox CTX API: predicted properties for DTXSID6023446 (Phencyclidine (PCP))","url":"https://comptox.epa.gov/ctx-api/chemical/property/predicted/search/by-dtxsid/DTXSID6023446"}],"sources_scope":"context","derived_markers":[],"warnings":["unmapped_classification:DEA:schedule ii","single_source_warning"],"meta":{"synthesis_version":"1.1.0","config_version":"1.1.0","n_sources":1,"db_version":44,"warnings":["unmapped_classification:DEA:schedule ii"]},"schema":"synthesis","_notice":"ALETHEIA output is reference data, not professional advice. Not a substitute for primary agency sources or qualified professionals. See https://aletheia.holisticquality.io/disclaimer.","_disclaimer_url":"https://aletheia.holisticquality.io/disclaimer","available_contexts":["human_adult","human_child","dog","human_teen","human_elderly","human_infant","human_pregnant","aquatic_life"]}